CervoMed Inc. financial data

Symbol
CRVO on Nasdaq
Location
20 Park Plaza, Suite 424, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Diffusion Pharmaceuticals Inc. (to 8/14/2023), RestorGenex Corp (to 1/14/2016), Stratus Media Group, Inc (to 3/7/2014), FERIS INTERNATIONAL, INC. (to 7/16/2008), TITAN MOTORCYCLE CO OF AMERICA INC (to 2/22/2008)
Latest financial report
10-K - Q4 2024 - Mar 17, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 9.28 %
Return On Equity 130 % +2223%
Return On Assets -42.6 % -43.6%
Operating Margin -187 % -71.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.7M shares +41%
Common Stock, Shares, Outstanding 8.7M shares +53.4%
Entity Public Float 91.6M USD
Common Stock, Value, Issued 8.7K USD +53.4%
Weighted Average Number of Shares Outstanding, Basic 8.07M shares +203%
Weighted Average Number of Shares Outstanding, Diluted 8.7M shares +131%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 9.74M USD +36.3%
Research and Development Expense 18.8M USD +123%
General and Administrative Expense 9.17M USD +40.6%
Operating Income (Loss) -18.2M USD -133%
Nonoperating Income (Expense) 1.94M USD -65.7%
Net Income (Loss) Attributable to Parent -16.3M USD -650%
Earnings Per Share, Basic -2.02 USD/shares -146%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9M USD +15.5%
Marketable Securities, Current 29.9M USD
Other Assets, Current 206K USD +193%
Assets, Current 43.1M USD +332%
Other Assets, Noncurrent 0 USD -100%
Assets 43.1M USD +332%
Accounts Payable, Current 1.51M USD +128%
Employee-related Liabilities, Current 250K USD -19.3%
Liabilities 3.88M USD +49.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 56.2K USD
Retained Earnings (Accumulated Deficit) -70.7M USD -29.9%
Stockholders' Equity Attributable to Parent 39.2M USD +431%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 5.34M USD
Liabilities and Equity 43.1M USD +332%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.42M USD +3.93%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 9.5M USD
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 8.7M shares +53.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.42M USD +3.93%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9M USD +15.5%
Deferred Tax Assets, Gross 18.9M USD +32.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -4.61M USD -314%
Deferred Tax Assets, Operating Loss Carryforwards 10.4M USD -0.75%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 30M shares
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 110M USD +77.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 18.6M USD +31.6%
Share-based Payment Arrangement, Expense 1.41M USD +245%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares